Cargando…

Osteopontin as a candidate of therapeutic application for the acute brain injury

Acute brain injury is the leading cause of human death and disability worldwide, which includes intracerebral haemorrhage, subarachnoid haemorrhage, cerebral ischaemia, traumatic brain injury and hypoxia‐ischaemia brain injury. Currently, clinical treatments for neurological dysfunction of acute bra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yunxiang, Yao, Yihan, Sheng, Lesang, Zhang, Jianmin, Zhang, John H., Shao, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417697/
https://www.ncbi.nlm.nih.gov/pubmed/32657030
http://dx.doi.org/10.1111/jcmm.15641
_version_ 1783569551017902080
author Zhou, Yunxiang
Yao, Yihan
Sheng, Lesang
Zhang, Jianmin
Zhang, John H.
Shao, Anwen
author_facet Zhou, Yunxiang
Yao, Yihan
Sheng, Lesang
Zhang, Jianmin
Zhang, John H.
Shao, Anwen
author_sort Zhou, Yunxiang
collection PubMed
description Acute brain injury is the leading cause of human death and disability worldwide, which includes intracerebral haemorrhage, subarachnoid haemorrhage, cerebral ischaemia, traumatic brain injury and hypoxia‐ischaemia brain injury. Currently, clinical treatments for neurological dysfunction of acute brain injury have not been satisfactory. Osteopontin (OPN) is a complex adhesion protein and cytokine that interacts with multiple receptors including integrins and CD44 variants, exhibiting mostly neuroprotective roles and showing therapeutic potential for acute brain injury. OPN‐induced tissue remodelling and functional repair mainly rely on its positive roles in the coordination of pro‐inflammatory and anti‐inflammatory responses, blood‐brain barrier maintenance and anti‐apoptotic actions, as well as other mechanisms such as affecting the chemotaxis and proliferation of nerve cells. The blood OPN strongly parallel with the OPN induced in the brain and can be used as a novel biomarker of the susceptibility, severity and outcome of acute brain injury. In the present review, we summarized the molecular signalling mechanisms of OPN as well as its overall role in different kinds of acute brain injury.
format Online
Article
Text
id pubmed-7417697
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74176972020-08-11 Osteopontin as a candidate of therapeutic application for the acute brain injury Zhou, Yunxiang Yao, Yihan Sheng, Lesang Zhang, Jianmin Zhang, John H. Shao, Anwen J Cell Mol Med Reviews Acute brain injury is the leading cause of human death and disability worldwide, which includes intracerebral haemorrhage, subarachnoid haemorrhage, cerebral ischaemia, traumatic brain injury and hypoxia‐ischaemia brain injury. Currently, clinical treatments for neurological dysfunction of acute brain injury have not been satisfactory. Osteopontin (OPN) is a complex adhesion protein and cytokine that interacts with multiple receptors including integrins and CD44 variants, exhibiting mostly neuroprotective roles and showing therapeutic potential for acute brain injury. OPN‐induced tissue remodelling and functional repair mainly rely on its positive roles in the coordination of pro‐inflammatory and anti‐inflammatory responses, blood‐brain barrier maintenance and anti‐apoptotic actions, as well as other mechanisms such as affecting the chemotaxis and proliferation of nerve cells. The blood OPN strongly parallel with the OPN induced in the brain and can be used as a novel biomarker of the susceptibility, severity and outcome of acute brain injury. In the present review, we summarized the molecular signalling mechanisms of OPN as well as its overall role in different kinds of acute brain injury. John Wiley and Sons Inc. 2020-07-13 2020-08 /pmc/articles/PMC7417697/ /pubmed/32657030 http://dx.doi.org/10.1111/jcmm.15641 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Zhou, Yunxiang
Yao, Yihan
Sheng, Lesang
Zhang, Jianmin
Zhang, John H.
Shao, Anwen
Osteopontin as a candidate of therapeutic application for the acute brain injury
title Osteopontin as a candidate of therapeutic application for the acute brain injury
title_full Osteopontin as a candidate of therapeutic application for the acute brain injury
title_fullStr Osteopontin as a candidate of therapeutic application for the acute brain injury
title_full_unstemmed Osteopontin as a candidate of therapeutic application for the acute brain injury
title_short Osteopontin as a candidate of therapeutic application for the acute brain injury
title_sort osteopontin as a candidate of therapeutic application for the acute brain injury
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417697/
https://www.ncbi.nlm.nih.gov/pubmed/32657030
http://dx.doi.org/10.1111/jcmm.15641
work_keys_str_mv AT zhouyunxiang osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury
AT yaoyihan osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury
AT shenglesang osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury
AT zhangjianmin osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury
AT zhangjohnh osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury
AT shaoanwen osteopontinasacandidateoftherapeuticapplicationfortheacutebraininjury